Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) yesterday and set a price target of $27. The company’s shares closed yesterday at $5.90.
Tanner noted:
“: We reiterate the Overweight rating and $27 PT for TXMD stock. We maintain our belief that the company is well positioned to improve the medical management of vulvar vaginal atrophy (VVA) and vasomotor symptoms (VMS) associated with menopause with Imvexxy and TX-001, respectively, and view the recent acquisition of contraceptive Annovera as making strategic sense.”
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 1.3% and a 47.2% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Intra-Cellular Therapies, and Evofem Biosciences Inc.
TherapeuticsMD has an analyst consensus of Strong Buy, with a price target consensus of $20.33, representing a 244.6% upside. In a report issued on September 26, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.
.
See today’s analyst top recommended stocks >>
Based on TherapeuticsMD’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.22 million. In comparison, last year the company had a GAAP net loss of $14.66 million.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
